登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由福建医科大学附属协和医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06601309,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Diagnosis: Histologically confirmed esophageal squamous cell carcinoma (ESCC).
入选标准第 1 条
Stage: Resectable locally advanced ESCC (clinical stage II-III according to the AJCC/UICC 8th edition).
入选标准第 2 条
Previous Treatment: Previous treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies.
排除标准第 6 条
Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
入选标准第 4 条
Other Malignancies: History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin carcinoma, or other localized non-invasive malignancy.
排除标准第 2 条
Pregnancy and Lactation: Pregnant or breastfeeding women. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization.
排除标准第 7 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06601309,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Diagnosis: Histologically confirmed esophageal squamous cell carcinoma (ESCC). Stage: Resectable locally advanced ESCC (clinical stage II-III according to the AJCC/UICC 8th edition). Age: 18-75 years old. Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. PD-L1 Expression: Available PD-L1 expression level (CPS). Surgical Eligibility: Assessed as eligible for surgical resection by a thoracic surgeon. Laboratory Requirements: Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L, Platelets ≥ 100 x 10\^9/L, Hemoglobin ≥ 9 g/dL. Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), AST and ALT ≤ 2.5 x ULN. Adequate renal function: Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 60 mL/min. Informed Consent: Ability to understand and willingness to sign a written informed consent document.排除标准:Exclusion Criteria:
Distant Metastasis: Presence of distant metastasis. Other Malignancies: History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin carcinoma, or other localized non-invasive malignancy. Autoimmune Diseases: History of active autoimmune diseases requiring systemic treatment within the past 2 years. Infections: Active infection requiring systemic therapy. Uncontrolled Conditions: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Previous Treatment: Previous treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies. Pregnancy and Lactation: Pregnant or breastfeeding women. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization. Allergies: Known allergy or hypersensitivity to study drugs or any excipient of these medications.
引自 ClinicalTrials.gov, NCT06601309, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06601309,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。